Australia raises AstraZeneca safety age to 60

Australia raises AstraZeneca safety age to 60

Australia raises AstraZeneca safety age to 60

AstraZeneca said in a statement, "The trial did not achieve the primary objective of preventing the emergence of symptomatic COVID-19 infections after exposure" to the virus.

Vials of the AstraZeneca COVID-19 vaccine and a syringe.

AstraZeneca's recent study of its monoclonal antibody treatment has revealed that it failed to prevent the symptomatic coronavirus in people who had been recently exposed to the virus.

The drug was in phase III development, in large-scale clinical trials, to test its safety and efficacy.

The results demonstrated that, in the overall trial population, AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to placebo - a result that is not statistically significant.

The trial involved 1,121 adults who did not receive the vaccine and had contact with an infected person during the previous eight days.

The company is nevertheless continuing trials to assess whether the drug can prevent Covid or treat more severe symptoms.

On March 16 this year, AstraZeneca had announced an extended agreement with the United States government to supply up to 5,00,000 additional doses of AZD7442 for $205 million, contingent on AZD7442 receiving Food and Drug Administration's emergency use authorisation in post-exposure prophylaxis.

A top official in the European Medicines Agency was on Sunday reported as having suggested that it might be worth abandoning AstraZeneca's vaccine if alternatives were available.

Other probable cases include a man from the Northern Territory aged 54, a 65-year-old woman in Tasmania, a 58-year old woman from South Australia and 59 and 80-year-old men from Queensland.

"It is clear that the risk-benefit ratio for individuals over 60 years of age is better", a EMA spokeswoman said.

A study from British health authorities published on Monday found that two doses of AstraZeneca/Oxford or rival Pfizer/BioNTech vaccines stopped the need for in-patient treatment in more than 90% of cases of the Delta variant.

Download the Eyewitness News app to your iOS or Android device.

Related news



[an error occurred while processing the directive]